HIGHLIGHTS
- who: Antoine Italiano from the Institut Bergonié, Bordeaux, France Faculty of Medicine, University of Bordeaux, Bordeaux have published the research work: Phase I study of daily and weekly regimens of the orally administered mdm2 antagonist idasanutlin in patients with advanced tumors, in the Journal: (JOURNAL) of November/15,/2011
- what: The aim of this first-in-human study was to investigate the maximum tolerated dose (MTD), characterize dose-limiting toxicity (DLT), and explore the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and clinical responses with idasanutlin with different dosing schedules. The safety population, defined as all . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.